Table 4.

Characteristics of patients who never developed viremia

Patient number	Indication for transplant	Conditionin gintensity	GVHD prophylaxis	EBV and CMV serostatus (donor/recipient)	Serotherapy	Transplant day at infusion	Status at last follow-up
2	AML	MAC MRD Marrow	Tacrolimus, MTX	CMV: −/+ EBV: −/+	None	21	Alive
3	Severe aplastic anemia	RICM UDP BSC	T-cell depletion	CMV: −/+ EBV: −/+	Alemtuzumab	22	Alive
8	HLH	RICM UDP BSC	CSA, prednisone	CMV: +/− EBV: +/+	Alemtuzumab	39	Alive
13	ALL	MAC MUD Marrow	CSA, MMF, abatacept	CMV: −/+ EBV: +/+	None	24	Dead, relapse, day 143
16	Hgb SD	RIC MRD Marrow	CSA, MTX, abatacept	CMV: −/− EBV: −/−	Alemtuzumab	22	Alive
19	ALL	MAC MRD Marrow	CSA, MMF	CMV: +/+ EBV: −/+	None	25	Alive
28	AML	RIC MRD PBSC	T-cell depletion	CMV: −/− EBV: +/+	Ex-vivo depletion only	24	Alive, relapse 6 mo after HSCT

ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CSA, cyclosporine A; Hgb, hemoglobin; HLH, hemophagocytic lymphohistiocytosis; MAC, myeloablative conditioning; MRD, matched related donor; MTX, methotrexate; MUD, matched unrelated donor; PBSC, peripheral blood stem cell; VST, virus-specific T cell.